These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 12592332

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro.
    Herrera L, Farah RA, Pellegrini VA, Aquino DB, Sandler ES, Buchanan GR, Vitetta ES.
    Leukemia; 2000 May; 14(5):853-8. PubMed ID: 10803517
    [Abstract] [Full Text] [Related]

  • 3. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
    Messmann RA, Vitetta ES, Headlee D, Senderowicz AM, Figg WD, Schindler J, Michiel DF, Creekmore S, Steinberg SM, Kohler D, Jaffe ES, Stetler-Stevenson M, Chen H, Ghetie V, Sausville EA.
    Clin Cancer Res; 2000 Apr; 6(4):1302-13. PubMed ID: 10778955
    [Abstract] [Full Text] [Related]

  • 4. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.
    Ghetie MA, Tucker K, Richardson J, Uhr JW, Vitetta ES.
    Blood; 1992 Nov 01; 80(9):2315-20. PubMed ID: 1384801
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
    Ghetie MA, May RD, Till M, Uhr JW, Ghetie V, Knowles PP, Relf M, Brown A, Wallace PM, Janossy G.
    Cancer Res; 1988 May 01; 48(9):2610-7. PubMed ID: 2451562
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains.
    Ghetie V, Engert A, Schnell R, Vitetta ES.
    Cancer Lett; 1995 Nov 27; 98(1):97-101. PubMed ID: 8529213
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency.
    Uckun FM, Manivel C, Arthur D, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Irvin JD, Myers DE, Gunther R.
    Blood; 1992 May 01; 79(9):2201-14. PubMed ID: 1373967
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life.
    Pop LM, Liu X, Ghetie V, Vitetta ES.
    Int Immunopharmacol; 2005 Jul 01; 5(7-8):1279-90. PubMed ID: 15914332
    [Abstract] [Full Text] [Related]

  • 17. Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia.
    Herrera L, Stanciu-Herrera C, Morgan C, Ghetie V, Vitetta ES.
    Leuk Lymphoma; 2006 Nov 01; 47(11):2380-7. PubMed ID: 17107913
    [Abstract] [Full Text] [Related]

  • 18. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
    Bonardi MA, French RR, Amlot P, Gromo G, Modena D, Glennie MJ.
    Cancer Res; 1993 Jul 01; 53(13):3015-21. PubMed ID: 7686448
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
    Jansen B, Vallera DA, Jaszcz WB, Nguyen D, Kersey JH.
    Cancer Res; 1992 Mar 01; 52(5):1314-21. PubMed ID: 1371092
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.